In consultation: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Consultation end date

Consultation end date

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 17 of 17

TitleConsultationTypeConsultation end date
Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer ID6304Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]Draft guidanceTechnology appraisal guidance
Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]Draft guidanceTechnology appraisal guidance
Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]Draft guidanceTechnology appraisal guidance
Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer [ID6589]Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity [ID6441]Final draft guidanceTechnology appraisal guidance
Anitocabtagene autoleucel for treating relapsed or refractory multiple myeloma ID6549Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Linvoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609]Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Sonrotoclax for treating relapsed or refractory mantle cell lymphoma after an anti-CD20 treatment and a BTK inhibitor [ID6654]Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma [ID6437]Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors (review of TA881) [ID6496]Final draft guidanceTechnology appraisal guidance
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]Final draft guidanceTechnology appraisal guidance
Norucholic acid for treating primary sclerosing cholangitis [ID6583]Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232]Draft guidanceTechnology appraisal guidance
Pegcetacoplan for treating complement 3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]Draft guidanceTechnology appraisal guidance
Bepirovirsen for treating chronic hepatitis B [ID6608]Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Rebisufligene etisparvovec for treating mucopolysaccharidosis type IIIA [ID6540]Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All